Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592638 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
A Phase 1 study of Small-cell Lung Cancer, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT06592638 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by Suzhou Zelgen Biopharmaceuticals Co.. The registered enrollment target is 30 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06592638, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.
Conditions Studied
Interventions
- DRUG ZG006
Study Locations (6)
Ohio
- Zelgen Site 101 - Canton
- Zelgen Site 104 - Cleveland
California
- Zelgen Site 105 - Orange
Florida
- Zelgen Site 102 - Plantation
Kentucky
- Zelgen Site 103 - Lexington
Texas
- Zelgen Site 106 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06592638
The ClinicalTrials.gov registry entry for NCT06592638 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Suzhou Zelgen Biopharmaceuticals Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZG006 is the first listed.
NCT06592638 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Ohio, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06592638 about?
NCT06592638 is a clinical study titled "A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer". This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recomme...
What is the current status of trial NCT06592638?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-31. Estimated completion is 2027-06.
What conditions does trial NCT06592638 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06592638?
The interventions under investigation include: ZG006 (DRUG).
Who is sponsoring clinical trial NCT06592638?
This trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592638 being conducted?
This trial has 6 study locations across California, Florida, Kentucky, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.